How the product works:
Inhibits RNA-dependent RNA polymerase, blocking viral replication
Rapidly reduces viral load
Helps relieve fever, sore throat, and cough
Shortens disease duration
Recommended for:
Adults with confirmed mild to moderate COVID-19
Patients with RNA-virus-induced influenza
Those prescribed antiviral therapy by a healthcare provider
Treatment of mild to moderate COVID-19
Influenza caused by RNA viruses
To be taken orally as directed by a physician. Usually starts with a loading dose followed by a reduced maintenance dose for 5–14 days. Can be taken with or without food, with water.
Contraindications:
Known hypersensitivity to Favipiravir
Pregnancy and breastfeeding
Severe liver or kidney impairment
Children under 18 years
Side effects:
Increased uric acid levels
Liver function abnormalities
Diarrhoea, nausea
Headache
Skin rash or itching
